Alignment Healthcare, Inc. (NASDAQ:ALHC), a leading Medicare Advantage insurer, recently announced its third-quarter 2025 earnings, showcasing a remarkable financial performance. The company achieved an EPS of $0.02, significantly surpassing the estimated EPS of -$0.01. This performance represents a substantial earnings surprise of 128.57%, as highlighted by the Zacks Consensus Estimate, which had anticipated a loss of $0.07 per share.
The company's revenue for the quarter was approximately $993.7 million, exceeding the estimated revenue of about $980.9 million. This represents a 1.30% increase over the Zacks Consensus Estimate and a significant rise from the $692.43 million reported in the same period last year. Over the past four quarters, ALHC has consistently exceeded consensus EPS estimates, showcasing its strong financial performance.
During the earnings call on October 30, 2025, key figures such as John Kao, the Founder, CEO, and Director, and James Head, the Chief Financial Officer, discussed the company's financial performance and strategic initiatives. The call was attended by analysts from prominent financial institutions, including Goldman Sachs, KeyBanc Capital Markets, and Piper Sandler, among others.
ALHC has a price-to-sales ratio of about 1.02 suggests that investors are paying $1.02 for every dollar of the company's sales, reflecting a reasonable valuation. The company's enterprise value to sales ratio is approximately 0.97, slightly lower than the price-to-sales ratio, indicating a relatively lower valuation when considering debt and cash. With a debt-to-equity ratio of about 2.34, ALHC has more than twice as much debt as equity. However, its current ratio of approximately 1.66 suggests a good level of liquidity to cover short-term liabilities.
